An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Tolebrutinib, an experimental drug, slowed disability progression in advanced MS by 31% in a major trial, offering hope for ...

Key Takeaways An experimental drug can delay disability progression in advanced multiple sclerosis patientsTolebrutinib ...

In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

A new study focused on transcription-replication conflicts, which occur when mechanisms responsible for gene expression and ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...